Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484045 | 0.90 | PDE7A (0.40) | PDE7AHTR2ASLC6A4KDM4EEGFR | |
| SCHEMBL3484533 | 0.81 | PDE7A (0.53) | PDE7AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL5307734 | 0.78 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDDDB1CRBN | |
| SCHEMBL3484193 | 0.78 | EGFR (0.49) | PDE7AHTR2ASLC6A4EGFRERBB2 | |
| SCHEMBL3485235 | 0.77 | CASP1 (0.46) | PDE7AHTR2ASLC6A4MAPK14 | |
| SCHEMBL3484991 | 0.76 | PARP1 (0.44) | HTR2A | |
| SCHEMBL3484137 | 0.76 | MRGPRX4 (0.42) | PDE7AKDM4EALDH1A1HPGDEGFR | |
| SCHEMBL3484686 | 0.75 | PDE7A (0.44) | PDE7AHTR2ASLC6A4KDM4EALDH1A1 | |
| SCHEMBL27768773 | 0.74 | HTR2A (0.38) | PDE7AHTR2ASLC6A4KDM4EMAPK14 | |
| SCHEMBL3485033 | 0.72 | EGFR (0.49) | PDE7AHTR2ASLC6A4EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | PDE7A 4340/4885HTR2A 1970/4885SLC6A4 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.